Global /South Korea /Healthcare /Medical Devices /176750

DuChemBIO Co.,Ltd.

176750

• KRX: 176750 • Delayed

9,120KRW 1.2%

5.95 USD

As of 5 June 2026, DuChemBIO Co.,Ltd. has a market cap of $168.65M USD, ranking #22165 globally and #917 in South Korea. It ranks #2001 in the Healthcare sector, and #414 in the Medical Devices industry.

Global Rank

22165

Country Rank

917

Sector Rank

2001

Industry Rank

414

Key Stats

Market Cap

$168.65MUSD

258.5B KRW

Enterprise Value

$174.52MUSD

267.51B KRW

Revenue (TTM)

$25.16MUSD

38.57B KRW

EBITDA (TTM)

$9.34MUSD

14.31B KRW

Net Income (TTM)

$4.23MUSD

6.48B KRW

EBITDA Margin

37%

Profit Margin

17%

PE Ratio

40.0

PS Ratio

6.7

PB Ratio

5.2

EV/EBITDA

18.7

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Medical Devices

CEO

Sang-Woo Kim open_in_new

Employees

126

Founded

2002

Website

duchembio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.2%	-1.1%	-3.7%	-0.4%	-7.3%	-5.4%	-18%	47%	-14%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	176750 (주)듀켐바이오 ISIN: KR7176750008 Shares Out.: Shares Outstanding: 28.378M¹ Shares Float: 10.994M² TV: TradingView: KRX: 176750 SA: Stock Analysis: KRX: 176750 YF: Yahoo Finance: 176750.KS GF: Google Finance: KRX: 176750 BA: Barron's: 176750 MS: Morningstar: XKRX: 176750	9,120 KRW	TV: TradingView: KRX: 176750 SA: Stock Analysis: KRX: 176750 YF: Yahoo Finance: 176750.KS GF: Google Finance: KRX: 176750 BA: Barron's: 176750 MS: Morningstar: XKRX: 176750

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About DuChemBIO Co.,Ltd.

DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

Similar Companies

Industry: Medical Devices (South Korea)

Name	Market Cap (USD) diff.	PE	Country
CLASSYS Inc. KRX: 214150	$2.45B 3.75T KRW 1K%	28.7	South Korea
SEERS Co., Ltd. KRX: 458870	$1.22B 1.86T KRW 621%	114.8	South Korea
Livsmed Inc. KRX: 491000	$1.18B 1.81T KRW 600%	-	South Korea
L&C BIO Co.,LTD KRX: 290650	$1.13B 1.74T KRW 572%	-	South Korea
Seegene, Inc. KRX: 096530	$753.63M 1.16T KRW 347%	23.9	South Korea
i3system Inc. KRX: 214430	$528.2M 809.64B KRW 213%	83.3	South Korea

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 103K%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 95K%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 94K%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 75K%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 71K%	38.3	United States
Medtronic plc NYSE: MDT	$101.9B 60K%	22.2	Ireland

chevron_leftBack